Falsolieva 250mg Injection (Fulvestrant): Targeted Endocrine Therapy for Advanced Breast Cancer Falsolieva 250 mg Injection is a specialized hormonal therapy containing the active ingredient Fulvestrant. It belongs to a class of medications known as selective estrogen receptor degraders (SERDs). Unlike traditional hormone therapies that merely block estrogen, Falsolieva works by significantly reducing the number of estrogen receptors in the body, providing a powerful intervention for hormone-receptor-positive (HR+) malignancies. Manufactured to meet global quality standards, Falsolieva is a critical tool for oncologists managing postmenopausal breast cancer. Therapeutic Indications: Clinical Scope HR-Positive Metastatic Breast Cancer: For postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer not previously treated with endocrine therapy. Progressive Advanced Breast Cancer: For women whose disease has progressed following anti-estrogen therapy (such as tamoxifen or aromatase inhibitors). Combination Therapy: Often used in combination with targeted therapies like CDK4/6 inhibitors (e.g., Palbociclib, Abemaciclib) to enhance clinical outcomes in metastatic settings. Mechanism of Action: How Falsolieva Works Competitive Binding: Fulvestrant binds to estrogen receptors (ER) with an affinity significantly higher than that of tamoxifen. Receptor Degradation: Once bound, it causes the estrogen receptor to change shape, leading to the degradation and eventual destruction of the receptor protein. Transcriptional Blockade: By reducing the number of available receptors, it prevents estrogen from “locking“ into the cancer cell, effectively stopping the signals that trigger tumor growth. No Agonist Effects: Unlike some other therapies, Falsolieva has no estrogen-mimicking effects, making it a pure antagonist. Professional Administration and Dosage Route of Administration: Falsolieva is administered as a slow intramuscular (IM) injection into the buttocks (gluteal area). Standard Dosing Regimen: The recommended dose is 500mg (administered as two 250mg injections, one in each buttock). Schedule: Typically administered on days 1, 15, and 29 of the first month, followed by once-monthly maintenance doses. Clinical Setting: Due to the specialized nature of the injection, it must be administered by a healthcare professional. Safety Profile and Patient Monitoring Injection Site Reactions: Temporary pain, inflammation, or bruising at the site of the IM injection. Hormonal Symptoms: Hot flashes, bone pain, and nausea are common but usually manageable. Hepatic Function: Liver function tests (LFTs) are recommended for patients with known hepatic impairment, as the drug is metabolized in the liver. Thromboembolic Events: While rare, monitoring for signs of blood clots is standard clinical practice for hormonal therapies. Why Choose Ernest Oncology? 100% Genuine Supply: We source Falsolieva directly from GMP-certified channels, ensuring every batch is authentic with an optimal shelf life. Global Distribution Reach: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Temperature-Controlled Logistics: Our team is expert in handling sensitive oncology products, ensuring they reach their destination under the required storage conditions. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals and pharmacy networks worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

Luprodex Injection: High-Efficacy Hormonal Therapy – Global Supply by Ernest Oncology In the advanced clinical landscape of 2026, Luprodex (Leuprolide Acetate) stands as a critical therapeutic agent for the management of hormone-responsive cancers and specialized gynecological conditions. As a synthetic analogue of the naturally occurring gonadotropin-releasing hormone (GnRH), Luprodex acts by suppressing the production of testosterone in men and estrogen in women, effectively inhibiting the growth of tumors that rely on these hormones to proliferate. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Luprodex to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated logistics and comprehensive pharmaceutical documentation for global procurement. Technical Product Profile: Luprodex (Leuprolide Acetate) Luprodex is available in multiple formulations, including daily injections and long-acting depot versions, designed to provide flexible dosing schedules for various clinical needs. Product Specifications Active Ingredient: Leuprolide Acetate. Dosage Strengths: Available in 3.75 mg, 11.25 mg, and 22.5 mg formulations. Mechanism of Action: GnRH Agonist; induces a state of “medical castration“ by down-regulating pituitary GnRH receptors, leading to a significant decrease in LH and FSH levels. Therapeutic Class: Antineoplastic Agent / Hormone Therapy. Storage Requirements: Store at controlled room temperature (below 25°C). Do not freeze. Primary Clinical Indications Prostate Cancer: Indicated for the palliative treatment of advanced prostatic adenocarcinoma, forming a cornerstone of Androgen Deprivation Therapy (ADT). Endometriosis: Management of endometriosis-associated pain and reduction of endometrial lesions. Uterine Fibroids: Used to reduce the size of leiomyomata (fibroids) prior to surgical intervention. Central Precocious Puberty (CPP): Treatment of pediatric patients with early-onset puberty. Key Features & Global Logistics Excellence Targeted Hormone Suppression: Proven to lower serum testosterone to castrate levels (< 50 ng/dL) effectively within the first few weeks of therapy. Flexible Administration: Multiple strengths allow for monthly, 3-monthly, or 6-monthly dosing cycles, enhancing patient convenience. Superior Supply Chain Integrity: Ernest Oncology ensures that Luprodex reaches oncology clinics and hospitals in London, Abu Dhabi, or Sydney with optimal shelf-life and strict quality control. Regulatory Compliance: Every shipment is accompanied by a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP), facilitating seamless customs clearance. Global Export Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology manages the complex regulatory requirements for exporting specialized hormonal therapies from India to major global healthcare hubs: USA: Reliable supply for urology clinics and oncology distributors seeking high-quality Leuprolide formulations. UK & London: Supporting NHS Trusts and private clinics with consistent access to essential hormonal treatments. Abu Dhabi, UAE: Catering to the advanced medical infrastructure of the Middle East with rapid and secure pharmaceutical delivery. Australia: Navigating TGA standards to provide Australian healthcare providers with authentic oncology medications. South Africa: Strengthening the Southern African oncology sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Luprodex and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Lupride Depot Injection: Advanced Hormonal Therapy for Oncology – Global Supply by Ernest Oncology In the evolving therapeutic landscape of 2026, Lupride Depot (Leuprolide Acetate) remains a gold-standard treatment for hormone-sensitive malignancies and reproductive health conditions. As a potent Gonadotropin-Releasing Hormone (GnRH) agonist, Lupride Depot works through a dual-phase mechanism: initially stimulating and subsequently desensitizing the pituitary gland. This leads to a profound suppression of testosterone in men and estrogen in women, effectively “starving“ hormone-dependent tumors. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Lupride Depot to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated logistics and comprehensive pharmaceutical documentation for global procurement. Technical Product Profile: Lupride Depot 3.75mg / 11.25mg / 22.5mg Lupride Depot is formulated as a lyophilized powder for microsphere-based sustained-release injection. This “Depot“ technology allows for consistent therapeutic drug levels over extended periods, ranging from one to six months depending on the dosage. Product Specifications Active Ingredient: Leuprolide Acetate. Dosage Strengths: Available in 3.75 mg (1-month), 11.25 mg (3-month), and 22.5 mg (6-month) depot formulations. Mechanism of Action: GnRH Agonist; induces medical castration by suppressing the hypothalamic-pituitary-gonadal axis. Therapeutic Class: Antineoplastic Agent / Hormone Therapy. Storage Requirements: Store at controlled room temperature (below 25°C). Do not freeze. Primary Clinical Indications Prostate Cancer: Palliative treatment of advanced prostatic adenocarcinoma; recognized as a primary tool in Androgen Deprivation Therapy (ADT). Endometriosis: Management of endometriosis, including pain relief and reduction of endometrial lesions. Uterine Fibroids: Preoperative treatment of patients with anemia caused by uterine leiomyomata (fibroids). Precocious Puberty: Treatment of central precocious puberty (CPP) in pediatric patients. Key Features & Global Logistics Excellence Sustained Release Precision: The microsphere technology ensures a steady release profile, reducing the frequency of injections and improving patient compliance. Clinically Validated Efficacy: Decades of clinical success in reducing serum testosterone to castrate levels (< 50 ng/dL) in prostate cancer patients. Superior Supply Chain Integrity: Ernest Oncology manages the end-to-end distribution, ensuring that Lupride Depot reaches oncology clinics in London, Abu Dhabi, or Sydney with optimal shelf-life and zero compromise in quality. Regulatory Compliance: Every shipment includes a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP), ensuring smooth customs clearance. Global Export Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology manages the complex regulatory requirements for exporting specialized hormonal therapies from India to major global healthcare hubs: USA: Supplying specialized urology and oncology centers with authentic Leuprolide Depot formulations. UK & London: Supporting NHS Trusts and private oncology networks with reliable access to cost-effective hormonal treatments. Abu Dhabi, UAE: Catering to the advanced medical infrastructure of the Middle East with rapid, secure delivery. Australia: Navigating TGA standards to provide Australian healthcare providers with essential oncology medications. South Africa: Strengthening the Southern African medical sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Lupride Depot and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhep Tablet: The Gold Standard in Chronic Hepatitis C Treatment – Global Supply by Ernest Oncology The medical landscape for Chronic Hepatitis C (HCV) was forever changed with the introduction of Direct-Acting Antivirals (DAAs). Myhep, featuring the breakthrough active ingredient Sofosbuvir (400mg), remains the foundation of most successful HCV treatment regimens. As a potent nucleotide analog polymerase inhibitor, Myhep is designed to stop the virus at its source, offering a pathway to a permanent cure for millions worldwide. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Myhep to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Myhep? (The Sofosbuvir Breakthrough) Myhep is a high-quality generic version of the world-renowned medication Sovaldi. It contains Sofosbuvir (400mg), which was the first drug to offer high cure rates with a simplified oral regimen. Before Sofosbuvir, treatment often involved grueling interferon injections with low success rates; Myhep has replaced that era with an effective, all-oral solution. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, & 4): Myhep is a versatile “backbone“ drug, usually used in combination with other antivirals (like Daclatasvir or Ledipasvir) to treat various HCV genotypes. HCV/HIV Co-infection: Proven safe for patients managing both conditions, maintaining a stable drug-interaction profile. Liver Transplant Candidates: Often used to prevent the recurrence of Hepatitis C in patients awaiting or recovering from a liver transplant. Detailed Product Information: Myhep (400mg) Feature, Technical Specification Active Ingredient, Sofosbuvir (400mg) Therapeutic Class Nucleotide Analog HCV NS5B Polymerase Inhibitor Manufacturer Mylan (Viatris) / Natco Pharma (India) Form, Film-coated tablets (28 Tablets per bottle) Standard Duration 12 to 24 Weeks (based on combination) Efficacy Rate >90% Sustained Virologic Response (SVR) Quality Standard GMP Certified Production Mechanism of Action: Chain Termination Myhep works by targeting the heart of the virus's replication machinery: NS5B Protein Inhibition: Sofosbuvir is a prodrug that, once inside the liver, converts into an active triphosphate. Stopping Replication: It mimics the natural building blocks of the virus's RNA. When the virus tries to use Myhep to build its genetic chain, the chain is “terminated,“ effectively stopping the virus from reproducing. Dosage and Administration Standard Regimen: One 400mg tablet taken once daily. Combination Therapy: Myhep is rarely used alone; it is typically taken with Ribavirin or another DAA (like Myhep DV). Administration: Can be taken with or without food. It is vital to take the tablet at the same time every day to ensure consistent antiviral levels. Storage: Store at room temperature (below 30°C) in its original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Myhep—manufactured in world-class Indian facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Daclahep Tablet: The Potent NS5A Inhibitor for Hepatitis C Cure – Global Supply by Ernest Oncology The evolution of Direct-Acting Antivirals (DAAs) has made Hepatitis C (HCV) a highly curable condition. Daclahep, containing Daclatasvir (60mg), is a cornerstone of modern HCV therapy. When used in combination with other antivirals like Sofosbuvir, it provides a robust, all-oral treatment pathway that targets the virus across multiple genotypes, ensuring high Sustained Virologic Response (SVR) rates. Ernest Oncology, the premier pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We specialize in the secure, GMP-certified international distribution of Daclahep to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa. What is Daclahep? Daclahep is a high-quality generic version of the breakthrough medication Daklinza. As a powerful NS5A inhibitor, it prevents the Hepatitis C virus from replicating and assembling new viral particles. Because it is rarely used alone, it is most commonly paired with Sofosbuvir to create a pan-genotypic treatment regimen that eliminates the need for interferon injections. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 3, & 4): Particularly effective when combined with Sofosbuvir for these prevalent genotypes. Advanced Liver Disease: A vital component for patients with compensated or decompensated cirrhosis. Post-Liver Transplant: Used in specialized regimens to prevent HCV recurrence after transplantation. HCV/HIV Co-infection: Highly recommended for patients managing both infections due to its favorable drug-interaction profile. Detailed Product Information: Daclahep (60mg) Feature, Technical Specification Active Ingredient: Daclatasvir (60mg) Drug Class: NS5A Replication Complex Inhibitor Manufacturer: Hetero Healthcare / Natco Pharma (India) Form film-coated tablets (28 Tablets per pack) Standard Regimen, 12 to 24 Weeks (based on clinical profile) Quality Standard, GMP Certified Manufacturing Mechanism of Action: Disrupting Viral Assembly Daclahep works by targeting a specific protein within the Hepatitis C virus: NS5A Protein Inhibition: Daclatasvir binds to the NS5A non-structural protein. This protein is essential for both the replication of the viral RNA and the assembly of the new virus particles (virions). Viral Clearance: By blocking this protein, the medication stops the virus from spreading to new liver cells, allowing the body’s immune system and companion antivirals to clear the infection. Dosage and Administration Standard Dose: One 60mg tablet taken orally, once daily. Combination Therapy: Must be taken with Sofosbuvir (400mg) or as directed by a hepatologist. Administration: Can be taken with or without food. Consistency is vital—doses should be taken at the same time every day. Storage: Store in a cool, dry place below 30°C, protected from light and moisture. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the complex logistics of international pharmaceutical trade. We ensure that Daclahep—manufactured by India's leading pharmaceutical giants—is delivered through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of oncology and antiviral medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Hepcinat Plus Tablet: The Advanced Dual-Action Cure for Hepatitis C – Global Supply by Ernest Oncology The introduction of Direct-Acting Antiviral (DAA) combinations has revolutionized the treatment of Chronic Hepatitis C, turning a once-chronic condition into a curable one. Hepcinat Plus, a potent fixed-dose combination of Sofosbuvir (400mg) and Daclatasvir (60mg), stands at the forefront of this medical breakthrough. This combination is highly effective across multiple genotypes and is widely prescribed for its high cure rates and manageable side-effect profile. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Hepcinat Plus to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Hepcinat Plus? Hepcinat Plus is a high-quality generic version of the combination therapy used to treat Chronic Hepatitis C. By combining two distinct antiviral mechanisms, Hepcinat Plus eliminates the need for interferon injections, which were previously the standard of care but carried significant side effects. Clinical data indicates a Sustained Virologic Response (SVR12)—the clinical definition of a cure—in over 95% of treated patients. Primary Indications & Medical Uses Chronic Hepatitis C (Multiple Genotypes): Specifically effective for Genotypes 1, 3, and 4, providing a robust treatment path for a wide range of patients. HCV/HIV Co-infection: Safe for use in patients managing both Hepatitis C and HIV-1, with a well-documented drug-interaction profile. Patients with Cirrhosis: Effective for patients with compensated liver disease, often used to prevent further liver damage and the need for transplantation. Detailed Product Information: Hepcinat Plus (400mg/60mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Daclatasvir (60mg) Drug Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer: Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Duration, Standard 12-Week Course Success Rate: >95% Sustained Virologic Response (SVR) Quality Standard, GMP Certified Production Mechanism of Action: The Dual-Inhibitor Strategy Hepcinat Plus works by attacking the Hepatitis C virus at two critical stages of its replication cycle: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ preventing the virus from copying its genetic material (RNA). Daclatasvir (60mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus requires for both the replication of the virus and the assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally, once daily. Administration: Can be taken with or without food. Consistency is critical; the dose should be taken at the same time every day to maintain optimal antiviral levels in the blood. Storage: Store in the original moisture-proof packaging at room temperature (below 30°C) away from direct sunlight. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Hepcinat Plus—manufactured by Natco Pharma—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ programs in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Sofocure V Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The landscape of Chronic Hepatitis C (HCV) treatment has reached a historic milestone with the development of “pan-genotypic“ therapies. Sofocure V, a high-potency fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), represents the gold standard in this evolution. Designed to eliminate the Hepatitis C virus across all six major genotypes, Sofocure V offers a simplified, once-daily oral regimen that achieves unprecedented cure rates. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, WHO-GMP-compliant international distribution of Sofocure V to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Sofocure V? (The Science of Eradication) Sofocure V is a premium generic version of the breakthrough medication Epclusa. It integrates two distinct Direct-Acting Antivirals (DAAs) that work synergistically to stop the virus from replicating and assembling new particles. Unlike traditional therapies of the past, Sofocure V is an all-oral regimen, removing the need for interferon injections and their associated severe side effects. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1–6): A universal treatment for all known HCV genotypes in adults and pediatric patients (3 years and older). Compensated Cirrhosis: Highly effective for patients with early-to-mid-stage liver scarring. Decompensated Cirrhosis: When combined with Ribavirin, it provides a life-saving treatment path for patients with advanced liver disease. HCV/HIV Co-infection: Proven safe for patients managing co-infection, maintaining a stable drug-interaction profile. Detailed Product Information: Sofocure V (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class: Antiviral (HCV NS5B & NS5A Inhibitor) Manufacturer: Emcure Pharmaceuticals (India) Treatment Duration: Standard 12-Week Course (84 Days) Form: Film-coated tablets (28 Tablets per bottle) Efficacy Rate: >95% Sustained Virologic Response (SVR12) Quality Standard, GMP-Certified Production Mechanism of Action: The Double-Inhibitor Strategy Sofocure V eradicates the virus by attacking two critical phases of its replication cycle: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ mimicking the building blocks of the virus to halt the replication of viral RNA. Velpatasvir (100mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus essentially requires for both the replication and assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally once per day. Administration: Can be taken with or without food. However, it is vital to take the tablet at the same time every day to maintain steady blood levels of the medication. Patient Compliance: Completing the full 12-week course is mandatory to prevent viral resistance and ensure a permanent cure. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Sofocure V—manufactured by Emcure Pharmaceuticals—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology networks and “Named Patient“ programs in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements, clinical research, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health departments, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Resof Total Tablet: The Ultimate Pan-Genotypic Breakthrough for Hepatitis C – Global Supply by Ernest Oncology The medical community has witnessed a paradigm shift in the treatment of Chronic Hepatitis C (HCV). Resof Total, a high-potency fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), represents the gold standard in “pan-genotypic“ therapy. This advanced formulation is designed to simplify the cure for all six major genotypes of the virus, offering a reliable pathway to viral eradication with a single daily tablet. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Resof Total to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Resof Total? (The Science of Eradication) Resof Total is a generic version of the breakthrough medication Epclusa. It combines two powerful Direct-Acting Antivirals (DAAs) that work synergistically to stop the Hepatitis C virus from replicating. Unlike older treatments that required interferon injections—which often came with severe side effects—Resof Total is an all-oral regimen with a superior safety profile. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1–6): The first-line choice for adults and pediatric patients (3 years and older) across all genotypes. Patients with Cirrhosis: Highly effective for those with compensated cirrhosis. Advanced Liver Disease: When combined with Ribavirin, it serves as a critical treatment for patients with decompensated cirrhosis. HCV/HIV Co-infection: Proven safe for patients managing both conditions simultaneously. Detailed Product Information: Resof Total (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Drug Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer: Dr. Reddy’s Laboratories (India) Form: Film-coated tablets (28 Tablets per bottle) Standard Duration, 12 Weeks (84 Days) Efficacy Rate > 97% Sustained Virologic Response (SVR12) Regulatory Status: Manufactured in GMP Certified Facilities Mechanism of Action: The Dual-Inhibitor Advantage Resof Total attacks the virus at two different stages of its life cycle, making it nearly impossible for the virus to develop resistance: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It mimics the building blocks the virus needs to copy its RNA but acts as a “chain terminator,“ stopping the replication process dead in its tracks. Velpatasvir (100mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus requires for both the replication and assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken once daily. Administration: Can be taken with or without food. However, consistency is key—patients should take the dose at the same time every day. Patient Compliance: It is critical to complete the full 12-week course, even if viral loads become undetectable early in the treatment, to ensure a permanent cure. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complexities of international pharmaceutical trade. We ensure that Resof Total—manufactured by Dr. Reddy’s Laboratories—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology networks and named-patient programs in London and across the UK. United States: Providing affordable access for clinical research, specialized pharmacies, and patient advocacy groups. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical diagnostic and treatment hubs. Australia & South Africa: Reliable bulk supply for public health departments, regional distributors, and NGOs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhep All Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The introduction of pan-genotypic Direct-Acting Antivirals (DAAs) has redefined the clinical approach to Chronic Hepatitis C (HCV). Myhep All, a potent fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), is at the forefront of this medical revolution. It is specifically engineered to treat all six major genotypes of the Hepatitis C Virus with a simplified, once-daily oral regimen, boasting cure rates that have effectively made HCV a manageable and eradicable disease. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We ensure the secure, verified international distribution of Myhep All to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa through specialized pharmaceutical logistics and cold-chain integrity. What is Myhep All? (The Science of SVR12) Myhep All is a high-quality, generic version of the breakthrough medication Epclusa. By combining two distinct antiviral mechanisms into a single film-coated tablet, Myhep All eliminates the need for painful interferon injections and, for the vast majority of patients, removes the requirement for Ribavirin. Clinical data indicates a Sustained Virologic Response (SVR12)—clinically defined as a cure—in 98% to 100% of patients without cirrhosis or with compensated cirrhosis. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, 4, 5, & 6): A universal treatment for all known HCV genotypes in adults and pediatric patients (3 years and older). Patients with Cirrhosis: Highly effective for both compensated and, when used in conjunction with Ribavirin, decompensated cirrhosis (advanced liver scarring). HCV/HIV Co-infection: Safe and effective for patients managing both Hepatitis C and HIV-1, with minimal drug-drug interactions. Detailed Product Information: Myhep All (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturers: Mylan (Viatris) / Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Duration: Standard 12-week course (84 days) Success Rate: >95% Sustained Virologic Response (SVR) Regulatory Standards, GMP & ISO Certified Manufacturing Mechanism of Action: The Dual-Blockade System Myhep All works by stopping the virus from replicating at two critical stages of its lifecycle: Sofosbuvir (400mg): This is an NS5B RNA-dependent RNA polymerase inhibitor. It acts as a “defective building block“ that terminates the viral RNA chain during replication, effectively stopping the virus from copying its genetic material. Velpatasvir (100mg): This targets the NS5A protein, which is essential for both the replication of the virus and the assembly of new viral particles. By blocking this protein, the virus cannot spread to healthy liver cells. Dosage and Administration Standard Regimen: One tablet taken once daily for a duration of 12 weeks. Administration: The tablet can be taken with or without food. It is vital to take the dose at the same time every day to maintain steady blood concentrations and prevent viral rebound. Storage: Store in the original moisture-proof packaging at room temperature (below 30°C) away from direct sunlight. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the global transit of life-saving specialty medicines. We navigate the complex regulatory environments of international pharmaceutical trade to ensure that Myhep All reaches patients and healthcare providers through legal and compliant trade channels. United Kingdom & London: Supporting private hepatology clinics and specialized “Named Patient“ programs throughout the UK. United States: Providing cost-effective access for specialized pharmacy requirements, clinical research, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383